Top 10 Cancer Drugs Market Size, Share, Industry Analysis, Trends, Growth, Forecasts, 2030

According to the report published by Zion Market Research, the global Top 10 Cancer Drugs Market size was valued at USD 79.85 billion in 2022 and is predicted to reach USD 149.52 billion by the end of 2030. The market is expected to grow with a CAGR of 9.38% during the forecast period. The report analyzes the global Top 10 Cancer Drugs market’s growth drivers, restraints, and impact on demand during the forecast period. It will also help navigate and explore the arising opportunities in the Top 10 Cancer Drugs industry.

Request Free Sample

Global Top 10 Cancer Drugs Market: Overview

Cancer is a disease in which the body’s cells grow uncontrollably anywhere in the body and can enter the adjoining body parts and spread to other organs. By far there are more than 200 types of cancer. Anything that can cause a normal body cell to grow abnormally can cause cancer. As every cancer type requires a specific treatment regimen, an accurate diagnosis of cancer is very crucial for effective and appropriate treatment.

Global Top 10 Cancer Drugs Market: Growth Factors

The global top 10 cancer drugs market is growing at a healthy rate. As per the data published by WHO, in 2020 across the world, in terms of new cases of cancer, the top five cancers include breast cancer (2.26 million new cases), lung (2.21 million new cases), colon & rectum (1.93 million new cases), prostate (1.41 million new cases), and skin (non-melanoma) (1.20 million new cases). Such a huge burden of diseases leads to socioeconomic loss. To reduce such a huge burden of diseases, as a treatment there is the use of chemotherapy, hormonal therapy, targeted therapy, and immunotherapy. Such a drastic rise in the prevalence of cancer is the major factor that is fueling the growth of the global market.

Additionally, NGOs and non-profit organizations supporting the treatment of cancer in developing countries, favorable reimbursement policies, and the presence of strong distribution channels are some of the factors that are fostering the growth of the global top 10 cancer drugs market. In addition to this, the growing use of combination therapy for the treatment of cancer and the rise in awareness regarding cancer & its treatment are also equally contributing to the growth of the market. Moreover, factors such as collaboration between the pharmaceutical companies for the manufacture & marketing of the top 10 cancer drugs in different countries, rise in demand for home care, and growing demand for effective cancer treatment are also the key aspects that are propelling the growth of the market.

Request Free Sample

Furthermore, rise in the studies and clinical trials to check the efficacy of the drugs in the treatment of multiple cancer indications may create opportunities for the growth of the global top 10 cancer drugs market during the forecast period. However, the high cost associated with the drugs may hinder the growth of the global top 10 cancer drugs market.

The global top 10 cancer drugs market is affected by the emergence of the Covid-19 pandemic. To curb the rapid spread of the infection, strict lockdown and restrictions on movement were imposed by most of the countries across the world. Also, the healthcare workers were majorly shifted towards the treatment of patients affected by the coronavirus as it has already infected millions of people and put tremendous pressure & challenges on the healthcare industry. All such factors coupled with disruption in distribution channels and suspension of all non-emergency procedures affected the market growth during the pandemic.

Global Top 10 Cancer Drugs Market: Regional Analysis

North America is predicted to account for maximum share in terms of revenue in the global top 10 cancer drugs market during the forecast period. Factors such as the adoption of advanced drug therapies, increase in prevalence of cancer, and presence of key manufacturers of the market are boosting the growth of the market in this region. Europe is expected to hold second position owing to favorable reimbursement policies and rise in healthcare expenditures. Asia Pacific is anticipated to grow at a faster rate during the forecast period. This is attributed to the rise in financial support by the non-profit organizations for cancer treatment, rise in demand for effective cancer treatment, and increase in healthcare expenditure.

Global Top 10 Cancer Drugs Market: Competitive Players

The nature of the global top 10 cancer drugs market is highly competitive owing to involvement of major biopharmaceuticals around the world. Key players in the market are adopting organic and inorganic strategies such as mergers & acquisitions and outsourcing to stay ahead in the competitive market.

The global Top 10 Cancer Drugs Market is led by players like:

• AbbVie Inc.
• Pfizer Inc.
• Novartis AG
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd.
• Celgene Corporation
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Astellas Pharma Inc. 

Global Top 10 Cancer Drugs Market: Regional Segment Analysis

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

What Reports Provides

• Full in-depth analysis of the parent market
• Important changes in market dynamics
• Segmentation details of the market
• Former, on-going, and projected market analysis in terms of volume and value
• Assessment of niche industry developments
• Market share analysis
• Key strategies of major players
• Emerging segments and regional markets
• Testimonials to companies in order to fortify their foothold in the market.